Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda continues Tak-536 development

Takeda continues Tak-536 development

25th June 2009

Takeda looks forward to developing Tak-536, it has said.

Phase III clinical trials of the investigational compound ? which is a novel angiotensin receptor blocker (ARB) ? have begun.

By inhibiting the action of the vasopressor hormone angiotensin II, it is able to lower blood pressure and is being investigated.

During the examinations, the compound is expected to show stronger anti-hypertensive action compared to Takeda’s marketed Blopress (candesartan cilexetil) and other available ARBs.

General manager of the company’s pharmaceutical development division Dr Nancy Joseph-Ridge noted hypertension is one of the most prevalent, modifiable risk factors for cardiovascular disease.

“Tak-536 is positioned to become the successor of Blopress ? and we expect it will further enhance Takeda’s cardiovascular franchise,” she said.

“We will look forward to continuing the development of Tak-536 and to providing it as soon as possible to hypertensive patients ? in order to better control their blood pressure.”

Last week, the business launched two new dose of Blopress Plus in Germany ? 25 mg and 12.5 mg.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.